Endocannabinoid concentrations in hair are associated with PTSD symptom severity

Psychoneuroendocrinology

Volumn 67, Issue , 2016, Pages 198-206

  Wilker, Sarah ^a   Pfeiffer, Anett ^b   Elbert, Thomas ^b   Ovuga, Emilio ^c   Karabatsiakis, Alexander ^a   Krumbholz, Aniko ^d   Thieme, Detlef ^d   Schelling, Gustav ^e   Kolassa, Iris Tatjana ^a  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY OF KONSTANZ   (Germany)

^c GULU UNIVERSITY   (Uganda)

^d Institute of Doping Analysis and Sports Biochemistry   (Germany)

^e UNIVERSITY OF MUNICH   (Germany)

Author keywords

Endocannabinoids; Hair; Mass spectrometry; Oleoylethanolamine; Palmitoylethanolamide; Posttraumatic stress disorder; Stearoylethanolamine

Indexed keywords

ENDOCANNABINOID; N ACYL ETHANOLAMIDE PALMITOYLETHANOLAMIDE; N OLEOYLETHANOLAMINE; STEAROYLETHANOLAMIDE; UNCLASSIFIED DRUG; ETHANOLAMINE DERIVATIVE; OLEIC ACID; PALMIDROL; PALMITIC ACID DERIVATIVE; STEARIC ACID DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENDOCANNABINOID HAIR LEVEL; FEAR; FEMALE; HAIR LEVEL; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MEMORY; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; STRUCTURED INTERVIEW; SURVIVOR; UGANDA; WAR; CASE CONTROL STUDY; HAIR; METABOLISM; PSYCHOLOGY; STRESS DISORDERS, POST-TRAUMATIC; VETERAN; YOUNG ADULT;

ADULT; CASE-CONTROL STUDIES; ENDOCANNABINOIDS; ETHANOLAMINES; FEMALE; HAIR; HUMANS; MALE; OLEIC ACIDS; PALMITIC ACIDS; STEARIC ACIDS; STRESS DISORDERS, POST-TRAUMATIC; UGANDA; VETERANS; YOUNG ADULT;

EID: 84958960015     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2016.02.010     Document Type: Article

References (61)

1. Amstadter A.B., Nugent N.R., Koenen K.C. Genetics of PTSD: fear conditioning as a model for future research. Psychiatr. Ann. 2009, 39(6):358-367. 10.3928/00485713-20090526-01.
2. Anderson K.C., Insel T.R. The promise of extinction research for the prevention and treatment of anxiety disorders. Biol. Psychiatry 2006, 60(4):319-321. 10.1016/j.biopsych.2006.06.022.
3. Baker D.G., Nievergelt C.M., O'Connor D.T. Biomarkers of PTSD: neuropeptides and immune signaling. Neuropharmacology 2012, 62(2):663-673. 10.1016/j.neuropharm.2011.02.027.
4. Bandiera T., Ponzano S., Piomelli D. Advances in the discovery of N-acylethanolamine acid amidase inhibitors. Pharmacol. Res. 2014, 86:11-17. 10.1016/j.phrs.2014.04.011.
5. Boscarino J.A. Posttraumatic stress disorder and physical illness: results from clinical and epidemiologic studies. Ann. N. Y. Acad. Sci. 2004, 1032:141-153. 10.1196/annals.1314.011.
6. Brewin C.R. Re-experiencing traumatic events in PTSD: new avenues in research on intrusive memories and flashbacks. Eur. J. Psychotraumatol. 2015, 6:27180. 10.3402/ejpt.v6.27180.
7. Campolongo P., Roozendaal B., Trezza V., Cuomo V., Astarita G., Fu J., McGaugh J.L., Piomelli D. Fat-induced satiety factor oleoylethanolamide enhances memory consolidation. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(19):8027-8031. 10.1073/pnas.0903038106.
8. Chouker A., Kaufmann I., Kreth S., Hauer D., Feuerecker M., Thieme D., Vogeser M., Thiel M., Schelling G. Motion sickness, stress and the endocannabinoid system. PLoS One 2010, 5(5):e10752. 10.1371/journal.pone.0010752.
9. de Bitencourt R.M., Pamplona F.A., Takahashi R.N. A current overview of cannabinoids and glucocorticoids in facilitating extinction of aversive memories: potential extinction enhancers. Neuropharmacology 2013, 64:389-395. 10.1016/j.neuropharm.2012.05.039.
10. Derogatis L.R., Lipman R.S., Rickels K., Uhlenhuth E.H., Covi L. The hopkins symptom checklist: a self-report symptom inventory. Behav. Sci. 1974, 19:1-15.
11. Dlugos A., Childs E., Stuhr K.L., Hillard C.J., de Wit H. Acute stress increases circulating anandamide and other N-acylethanolamines in healthy humans. Neuropsychopharmacology 2012, 37(11):2416-2427. 10.1038/npp.2012.100.
12. Ehlers A., Hackmann A., Michael T. Intrusive re-experiencing in post-traumatic stress disorder: phenomenology, theory, and therapy. Memory 2004, 12(4):403-415. 10.1080/09658210444000025.
13. Ertl V., Pfeiffer A., Saile R., Schauer E., Elbert T., Neuner F. Validation of a mental health assessment in an african conflict population. Psychol. Assess. 2010, 22(2):318-324. 10.1037/a0018810.
14. Farr O.M., Ko B.J., Joung K.E., Zaichenko L., Usher N., Tsoukas M., Thakkar B., Davis C.R., Crowell J.A., Mantzoros C.S. Posttraumatic stress disorder, alone or additively with early life adversity, is associated with obesity and cardiometabolic risk. Nutr. Metab. Cardiovasc. Dis.: NMCD 2015, 25(5):479-488. 10.1016/j.numecd.2015.01.007.
15. Feuerecker M., Hauer D., Toth R., Demetz F., Holzl J., Thiel M., Kaufmann I., Schelling G., Chouker A. Effects of exercise stress on the endocannabinoid system in humans under field conditions. Eur. J. Appl. Physiol. 2012, 112(7):2777-2781. 10.1007/s00421-011-2237-0.
16. Foa E.B. Posttraumatic Stress Diagnostic Scale Manual 1995, National Computer Systems, Minneapolis.
17. Fu J., Oveisi F., Gaetani S., Lin E., Piomelli D. Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats. Neuropharmacology 2005, 48(8):1147-1153. S0028-3908(05)00089-4.
18. Fuss J., Steinle J., Bindila L., Auer M.K., Kirchherr H., Lutz B., Gass P. A runner's high depends on cannabinoid receptors in mice. Proc. Natl. Acad. Sci. U. S. A. 2015, 112(42):13105-13108. 10.1073/pnas.1514996112.
19. Gavrieli A., Farr O.M., Davis C.R., Crowell J.A., Mantzoros C.S. Early life adversity and/or posttraumatic stress disorder severity are associated with poor diet quality, including consumption of trans fatty acids, and fewer hours of resting or sleeping in a US middle-aged population: a cross-sectional and prospective study. Metabolism 2015, 64(11):1597-1610. 10.1016/j.metabol.2015.08.017.
20. Glaesmer H., Brahler E., Gündel H., Riedel-Heller S.G. The association of traumatic experiences and posttraumatic stress disorder with physical morbidity in old age: a german population-based study. Psychosom. Med. 2011, 73(5):401-406. 10.1097/PSY.0b013e31821b47e8.
21. Gola H., Engler H., Sommershof A., Adenauer H., Kolassa S., Schedlowski M., Groettrup M., Elbert T., Kolassa I.T. Posttraumatic stress disorder is associated with an enhanced spontaneous production of pro-inflammatory cytokines by peripheral blood mononuclear cells. BMC Psychiatry 2013, 13:40. 10.1186/1471-244X-13-40.
22. Gunduz-Cinar O., MacPherson K.P., Cinar R., Gamble-George J., Sugden K., Williams B., Godlewski G., Ramikie T.S., Gorka A.X., Alapafuja S.O., Nikas S.P., Makriyannis A., Poulton R., Patel S., Hariri A.R., Caspi A., Moffitt T.E., Kunos G., Holmes A. Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity. Mol. Psychiatry 2013, 18(7):813-823. 10.1038/mp.2012.72.
23. Hauer D., Schelling G., Gola H., Campolongo P., Morath J., Roozendaal B., Humuni G., Karabatsiakis A., Atsak P., Vogeser M., Kolassa I.T. Plasma concentrations of endocannabinoids and related primary fatty acid amides in patients with post-traumatic stress disorder. PLoS One 2013, 8(5):e62741. 10.1371/journal.pone.0062741.
24. Henderson G.L. Mechanisms of drug incorporation into hair. Forensic Sci. Int. 1993, 63(1-3):19-29. 0379-0738(93) 90256-A.
25. Hill M.N., Bierer L.M., Makotkine I., Golier J.A., Galea S., McEwen B.S., Hillard C.J., Yehuda R. Reductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the world trade center attacks. Psychoneuroendocrinology 2013, 38(12):2952-2961. 10.1016/j.psyneuen.2013.08.004.
26. Hill M.N., McEwen B.S. Involvement of the endocannabinoid system in the neurobehavioural effects of stress and glucocorticoids. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2010, 34(5):791-797. 10.1016/j.pnpbp.2009.11.001.
27. Hill M.N., Miller G.E., Carrier E.J., Gorzalka B.B., Hillard C.J. Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress. Psychoneuroendocrinology 2009, 34(8):1257-1262. 10.1016/j.psyneuen.2009.03.013.
28. Hill M.N., Patel S. Translational evidence for the involvement of the endocannabinoid system in stress-related psychiatric illnesses. Biol. Mood Anxiety Disord. 2013, 3(1):19. 10.1186/2045-5380-3-19.
29. Ho W.S., Barrett D.A., Randall M.D. 'Entourage' effects of N-palmitoylethanolamide and N-oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors. Br. J. Pharmacol. 2008, 155(6):837-846. 10.1038/bjp.2008.324.
30. Holman E.A., Guijarro A., Lim J., Piomelli D. Effects of acute stress on cardiac endocannabinoids, lipogenesis, and inflammation in rats. Psychosom. Med. 2014, 76(1):20-28. 10.1097/PSY.0000000000000025.
31. Jetly R., Heber A., Fraser G., Boisvert D. The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: a preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology 2015, 51:585-588. 10.1016/j.psyneuen.2014.11.002.
32. Jonsson K.O., Vandevoorde S., Lambert D.M., Tiger G., Fowler C.J. Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide. Br. J. Pharmacol. 2001, 133(8):1263-1275. 10.1038/sj.bjp.0704199.
33. Karabatsiakis A., Hamuni G., Wilker S., Kolassa S., Renu D., Kadereit S., Schauer M., Hennessy T., Kolassa I.T. Metabolite profiling in posttraumatic stress disorder. J. Mol. Psychiatry 2015, 3(1):2. 10.1186/s40303-015-0007-3.
34. Kirschbaum C., Tietze A., Skoluda N., Dettenborn L. Hair as a retrospective calendar of cortisol production-increased cortisol incorporation into hair in the third trimester of pregnancy. Psychoneuroendocrinology 2009, 34(1):32-37. 10.1016/j.psyneuen.2008.08.024.
35. Klumpers F., Denys D., Kenemans J.L., Grillon C., van der Aart J., Baas J.M. Testing the effects of delta9-THC and D-cycloserine on extinction of conditioned fear in humans. J. Psychopharmacol. 2012, 26(4):471-478. 10.1177/0269881111431624.
36. Kolassa I.T., Ertl V., Eckart C., Glockner F., Kolassa S., Papassotiropoulos A., de Quervain D.J., Elbert T. Association study of trauma load and SLC6A4 promoter polymorphism in posttraumatic stress disorder: evidence from survivors of the rwandan genocide. J. Clin. Psychiatry 2010, 71(5):543-547. 10.4088/JCP.08m04787blu.
37. Kolassa I.T., Ertl V., Kolassa S., Onyut L.P., Elbert T. The probability of spontaneous remission from PTSD depends on the number of traumatic event types experienced. Psychol. Trauma 2010, 3(3):169-174. 10.1037/a0019362.
38. Kolassa I.T., Kolassa S., Ertl V., Papassotiropoulos A., De Quervain D.J. The risk of posttraumatic stress disorder after trauma depends on traumatic load and the catechol-o-methyltransferase val(158) met polymorphism. Biol. Psychiatry 2010, 67(4):304-308. 10.1016/j.biopsych.2009.10.009.
39. Krumbholz A., Anielski P., Reisch N., Schelling G., Thieme D. Diagnostic value of concentration profiles of glucocorticosteroids and endocannabinoids in hair. Ther. Drug Monit. 2013, 35(5):600-607. 10.1097/FTD.0b013e3182953e43.
40. Morena M., Patel S., Bains J.S., Hill M.N. Neurobiological interactions between stress and the endocannabinoid system. Neuropsychopharmacology 2015, 10.1038/npp.2015.166.
41. Neumeister A., Normandin M.D., Pietrzak R.H., Piomelli D., Zheng M.Q., Gujarro-Anton A., Potenza M.N., Bailey C.R., Lin S.F., Najafzadeh J., Ropchan J., Henry S., Corsi-Travali S., Carson R.E., Huang Y. Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study. Mol. Psychiatry 2013, 18(9):1034-1040. 10.1038/mp.2013.61.
42. Neumeister A., Seidel J., Ragen B.J., Pietrzak R.H. Translational evidence for a role of endocannabinoids in the etiology and treatment of posttraumatic stress disorder. Psychoneuroendocrinology 2015, 51:577-584. 10.1016/j.psyneuen.2014.10.012.
43. O'Sullivan S.E., Kendall D.A. Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease. Immunobiology 2010, 215(8):611-616. 10.1016/j.imbio.2009.09.007.
44. Papini S., Sullivan G.M., Hien D.A., Shvil E., Neria Y. Toward a translational approach to targeting the endocannabinoid system in posttraumatic stress disorder: a critical review of preclinical research. Biol. Psychol. 2015, 104:8-18. 10.1016/j.biopsycho.2014.10.010.
45. Rabinak C.A., Angstadt M., Lyons M., Mori S., Milad M.R., Liberzon I., Phan K.L. Cannabinoid modulation of prefrontal-limbic activation during fear extinction learning and recall in humans. Neurobiol. Learn. Mem. 2014, 113:125-134. 10.1016/j.nlm.2013.09.009.
46. Rabinak C.A., Angstadt M., Sripada C.S., Abelson J.L., Liberzon I., Milad M.R., Phan K.L. Cannabinoid facilitation of fear extinction memory recall in humans. Neuropharmacology 2013, 64:396-402. 10.1016/j.neuropharm.2012.06.063.
47. Roberts A.L., Agnew-Blais J.C., Spiegelman D., Kubzansky L.D., Mason S.M., Galea S., Hu F.B., Rich-Edwards J.W., Koenen K.C. Posttraumatic stress disorder and incidence of type 2 diabetes mellitus in a sample of women: a 22-year longitudinal study. JAMA Psychiatry 2015, 72(3):203-210. 10.1001/jamapsychiatry.2014.2632.
48. Rodriguez de Fonseca F., Navarro M., Gomez R., Escuredo L., Nava F., Fu J., Murillo-Rodriguez E., Giuffrida A., LoVerme J., Gaetani S., Kathuria S., Gall C., Piomelli D. An anorexic lipid mediator regulated by feeding. Nature 2001, 414(6860):209-212. 10.1038/35102582.
49. Roitman P., Mechoulam R., Cooper-Kazaz R., Shalev A. Preliminary, open-label, pilot study of add-on oral delta9-tetrahydrocannabinol in chronic post-traumatic stress disorder. Clin. Drug Invest. 2014, 34(8):587-591. 10.1007/s40261-014-0212-3.
50. Rosenbaum S., Stubbs B., Ward P.B., Steel Z., Lederman O., Vancampfort D. The prevalence and risk of metabolic syndrome and its components among people with posttraumatic stress disorder: a systematic review and meta-analysis. Metabolism 2015, 64(8):926-933. 10.1016/j.metabol.2015.04.009.
51. Rosenbaum S., Vancampfort D., Steel Z., Newby J., Ward P.B., Stubbs B. Physical activity in the treatment of post-traumatic stress disorder: a systematic review and meta-analysis. Psychiatry Res. 2015, 230(2):130-136. 10.1016/j.psychres.2015.10.017.
52. Sayd A., Anton M., Alen F., Caso J.R., Pavon J., Leza J.C., Rodriguez de Fonseca F., Garcia-Bueno B., Orio L. Systemic administration of oleoylethanolamide protects from neuroinflammation and anhedonia induced by LPS in rats. Int. J. Neuropsychopharmacol. 2015, 18(6). 10.1093/ijnp/pyu111.
53. Schaefer C., Enning F., Mueller J.K., Bumb J.M., Rohleder C., Odorfer T.M., Klosterkotter J., Hellmich M., Koethe D., Schmahl C., Bohus M., Leweke F.M. Fatty acid ethanolamide levels are altered in borderline personality and complex posttraumatic stress disorders. Eur. Arch. Psychiatry Clin. Neurosci. 2014, 264(5):459-463. 10.1007/s00406-013-0470-8.
54. Seng J.S., Clark M.K., McCarthy A.M., Ronis D.L. PTSD and physical comorbidity among women receiving medicaid: results from service-use data. J. Trauma Stress 2006, 19(1):45-56. 10.1002/jts.20097.
55. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar G.C. The mini-international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998, 59(Suppl. 20):22-33. quiz 34-57.
56. Thabuis C., Tissot-Favre D., Bezelgues J.B., Martin J.C., Cruz-Hernandez C., Dionisi F., Destaillats F. Biological functions and metabolism of oleoylethanolamide. Lipids 2008, 43(10):887-894. 10.1007/s11745-008-3217-y.
57. Vaughn L.K., Denning G., Stuhr K.L., de Wit H., Hill M.N., Hillard C.J. Endocannabinoid signalling: Has it got rhythm?. Br. J. Pharmacol. 2010, 160(3):530-543. 10.1111/j.1476-5381.2010.00790.x.
58. von Kanel R., Hepp U., Kraemer B., Traber R., Keel M., Mica L., Schnyder U. Evidence for low-grade systemic proinflammatory activity in patients with posttraumatic stress disorder. J. Psychiatr. Res. 2007, 41(9):744-752. 10.1016/j.jpsychires.2006.06.009.
59. Wilker S., Pfeiffer A., Kolassa S., Koslowski D., Elbert T., Kolassa I.T. How to quantify exposure to traumatic stress? Reliability and predictive validity of measures for cumulative trauma exposure in a post-conflict population. Eur. J. Psychotraumatol. 2015, 6(28306). 10.3402/ejpt.v6.28306.
60. Wilker S., Elbert T., Kolassa I.T. The downside of strong emotional memories: how human memory-related genes influence the risk for posttraumatic stress disorder-a selective review. Neurobiol. Learn. Mem. 2014, 112:75-86. 10.1016/j.nlm.2013.08.015.
61. Wilker S., Kolassa I.T. The formation of a neural fear network in posttraumatic stress disorder: insights from molecular genetics. Clin. Psychol. Sci. 2013, 1(4):452-469. 10.1177/2167702613479583.